Live Chat

What Did the FDA Advise Paxil Patients?

For pregnant women and their in utero children, the risks associated with Paxil (paroxetine) are sufficiently concerning that the Food and Drug Administration (FDA) has warned patients and health care professionals that this widely prescribed antidepressant may increase the risk of birth defects in general and, in particular, heart defects. The risks were so significant, in fact, that the FDA also advised the relabeling of Paxil, from a class C to a class D drug.

 

Sadly, too many patients know first-hand about the risks of Paxil. What you may not know, however, is that if your child was born with a Paxil-related birth defect, you may be entitled to compensation for your child’s and your family’s physical pain and mental suffering. Legal action in this area is important – not just as a way of protecting your family’s legal and financial interests, but also as a way of holding the maker of Paxil accountable for their decisions. Do you have questions about how you might proceed? Do you need more information? Find out the answer to many of your questions by talking to the professionals at Fears Nachawati. For your free consultation, call us at 1.866.545.8364 or email mn@fnlawfirm.com. We’re ready to fight for you!

Categories
Drug Litigation

What Did the FDA Advise Paxil Patients?